In the BioHarmony Drug Report Database
Vemurafenib
Zelboraf (vemurafenib) is a small molecule pharmaceutical. Vemurafenib was first approved as Zelboraf on 2011-08-17. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against serine/threonine-protein kinase B-raf. In addition, it is known to target RAF proto-oncogene serine/threonine-protein kinase. Zelboraf’s patents are valid until 2032-06-06 (FDA).
Trade Name
|
Zelboraf |
|---|---|
Common Name
|
vemurafenib |
ChEMBL ID
|
CHEMBL1229517 |
Indication
|
melanoma |
Drug Class
|
Raf kinase inhibitors |
Image (chem structure or protein)